Pacific BiosciencesPACB
Market Cap: $431M
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 796
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
37% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 59
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
10.45% less ownership
Funds ownership: 99.42% [Q1] → 88.97% (-10.45%) [Q2]
15% less funds holding
Funds holding: 262 [Q1] → 224 (-38) [Q2]
21% less call options, than puts
Call options by funds: $2.38M | Put options by funds: $3M
53% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 72
67% less capital invested
Capital invested by funds: $1.01B [Q1] → $332M (-$675M) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Scotiabank Sung Ji Nam 50% 1-year accuracy 7 / 14 met price target | 343%upside $7 | Sector Outperform Maintained | 28 Aug 2024 |
Morgan Stanley Tejas Savant 69% 1-year accuracy 11 / 16 met price target | 27%upside $2 | Equal-Weight Maintained | 12 Aug 2024 |
Cantor Fitzgerald Ross Osborn 32% 1-year accuracy 19 / 60 met price target | 122%upside $3.50 | Overweight Reiterated | 8 Aug 2024 |
Canaccord Genuity Kyle Mikson 38% 1-year accuracy 8 / 21 met price target | 90%upside $3 | Buy Maintained | 8 Aug 2024 |
Financial journalist opinion
Based on 51 articles about PACB published over the past 30 days